Podcast
MSL Talk: Tom Caravela, Mike Penkethman
How and Why Medical Affairs Can Support Diversity in Clinical Trials
Summary
In this episode, Tom Caravela is joined by Brad Atkinson, Brian Wilson, and Christina Wright to explore the critical role of diversity in clinical trials and the MSL’s part in fostering inclusivity. The discussion covers FDA guidance on diversity, challenges in therapeutic areas, and the importance of patient-centric approaches. The speakers delve into the strategic roles of MSLs in education and the historical context of diversity in clinical trials. They provide actionable strategies for field medical teams to enhance trial diversity and emphasize the significance of cultural awareness and allyship. The episode concludes with reflections and a call to action for promoting diversity in medical settings.
Christina Wright, Brad Atkinson and Brian Wilson discuss the important role Medical Affairs/MSLs can play in supporting diversity in clinical trials
The group discusses…
👉 Why does medical affairs need to be involved in diversity clinical trial initiatives?
👉 How can field medical get comfortable with the D and I conversation?
👉 What resources can be helpful
👉 3 Pillars of “Allyship”
👉 Why insights are currency
diversity in clinical trials, role of MSLs, FDA guidance on diversity, patient-centric approaches, cultural awareness and allyship
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mike Penkethman
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official